Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
Conditions: SLE (Systemic Lupus); Sjogren's Syndrome; Systemic Scleroderma; Dermatomyositis; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Intervention: Biological: CD19 targeted CAR-T cells Sponsor: Chongqing Precision Biotech Co., Ltd Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Autoimmune Disease | Biotechnology | Dermatology | Dermatomyositis | Lupus | Research | Scleroderma | Vasculitis